NCT01122615View on ClinicalTrials.gov

Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Renal Cell CancerKidney Cancer
Interventions
DRUG

Sunitinib

12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.

DRUG

Temsirolimus

6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER